Case Files of the New York City Poison Control Center: Paradichlorobenzene-Induced Leukoencephalopathy

Journal of Medical Toxicology

Volumn 6, Issue 2, 2010, Pages 217-229

  Hernandez, Stephanie H ^a,b   Wiener, Sage W ^c   Smith, Silas W ^a,b  

^a NEW YORK CITY POISON CONTROL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Ataxia; Encephalopathy; Leukoencephalopathy; Moth ball(s); Paradichlorobenzene; White matter disease

Indexed keywords

1,4 DICHLOROBENZENE; ACICLOVIR; FOLIC ACID; IRON; LORAZEPAM; PHENYTOIN; QUETIAPINE; THIAMINE; VALPROIC ACID;

ADULT; ALCOHOL CONSUMPTION; ANOREXIA; ARTICLE; BEHAVIOR CHANGE; BLOOD ANALYSIS; BLUNTED AFFECT; CANNABIS SMOKING; CASE REPORT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; EMERGENCY HEALTH SERVICE; FLUID THERAPY; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; LEUKOENCEPHALOPATHY; MALE; MEDICAL RECORD; MENTAL DEFICIENCY; NUCLEAR MAGNETIC RESONANCE IMAGING; POISON CENTER; PSYCHOSOCIAL WITHDRAWAL; TOXIN ANALYSIS; UNITED STATES; WEIGHT REDUCTION;

ADULT; BLOOD CHEMICAL ANALYSIS; CHLOROBENZENES; HUMANS; INSECTICIDES; KIDNEY DISEASES; LEUKOENCEPHALOPATHIES; MAGNETIC RESONANCE IMAGING; MALE; NEUROLOGIC EXAMINATION; NEW YORK CITY; PICA; POISON CONTROL CENTERS; SUBSTANCE-RELATED DISORDERS; XENOBIOTICS;

EID: 77956138728     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-010-0053-2     Document Type: Article

References (122)

1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334: 494-500.
2. Sharshar T, Gray F, Poron F, Raphael JC, Gajdos P, Annane D (2002) Multifocal necrotizing leukoencephalopathy in septic shock. Crit Care Med 30: 2371-2375.
3. van der Knaap MS, Breiter SN, Naidu S, Hart AA, Valk J (1999) Defining and categorizing leukoencephalopathies of unknown origin: MR imaging approach. Radiology 213: 121-133.
4. Hesselink JR (2006) Differential diagnostic approach to MR imaging of white matter diseases. Top Magn Reson Imaging 17: 243-263.
5. Costello DJ, Eichler AF, Eichler FS (2009) Leukodystrophies: classification, diagnosis, and treatment. Neurologist 15: 319-328.
6. Vanderver A (2005) Tools for diagnosis of leukodystrophies and other disorders presenting with white matter disease. Curr Neurol Neurosci Rep 5: 110-118.
7. Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J (1991) Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 70: 229-245.
8. Chatterjee A, Yapundich R, Palmer CA, Marson DC, Mitchell GW (1996) Leukoencephalopathy associated with cobalamin deficiency. Neurology 46: 832-834.
9. 12, folic acid, and the nervous system. Lancet Neurol 5: 949-960.
10. Celik O, Hascalik S (2003) Reversible posterior leukoencephalopathy in eclampsia. Int J Gynaecol Obstet 82: 67-69.
11. Rosenberg GA (2009) Inflammation and white matter damage in vascular cognitive impairment. Stroke 40: S20-S23.
12. Oh U, Gupta R, Krakauer JW, Khandji AG, Chin SS, Elkind MS (2004) Reversible leukoencephalopathy associated with cerebral amyloid angiopathy. Neurology 62: 494-497.
13. Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW (2009) Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis 9: 625-636.
14. Gongvatana A, Schweinsburg BC, Taylor MJ, Theilmann RJ, Letendre SL, Alhassoon OM, Jacobus J, Woods SP, Jernigan TL, Ellis RJ, Frank LR, Grant I, Charter Group (2009) White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirology 15: 187-195.
15. Souraud JB, Faivre A, Waku-Kouomou D, Gaillard T, Aouad N, Meaudre E, Wild FT, Fouet B, Soulard R (2009) Adult fulminant subacute sclerosing panencephalitis: pathological and molecular studies-a case report. Clin Neuropathol 28: 213-218.
16. Hu W, Lucchinetti CF (2009) The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol 31: 439-453.
17. Canellas AR, Gols AR, Izquierdo JR, Subirana MT, Gairin XM (2007) Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology 49: 393-409.
18. Fleming FJ, Vytopil M, Chaitow J, Jones HR Jr, Darras BT, Ryan MM (2005) Thalidomide neuropathy in childhood. Neuromuscul Disord 15: 172-176.
19. Burns TM, Shneker BF, Juel VC (2001) Gasoline sniffing multifocal neuropathy. Pediatr Neurol 25: 419-421.
20. Smith AG, Albers JW (1997) n-Hexane neuropathy due to rubber cement sniffing. Muscle Nerve 20: 1445-1450.
21. Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13: 27-46.
22. Berger AR, Schaumburg HH, Schroeder C, Apfel S, Reynolds R (1992) Dose response, coasting, and differential fiber vulnerability in human toxic neuropathy: a prospective study of pyridoxine neurotoxicity. Neurology 42: 1367-1370.
23. Berger AR, Arezzo JC, Schaumburg HH, Skowron G, Merigan T, Bozzette S, Richman D, Soo W (1993) 2′, 3′-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 43: 358-362.
24. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M (2006) CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5: 22.
25. Crossen JR, Garwood D, Glatstein E, Neuwelt EA (1994) Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12: 627-642.
26. Giglio P, Gilbert MR (2003) Cerebral radiation necrosis. Neurologist 9: 180-188.
27. Blaes AH, Santa-Cruz KS, Lee CK, Hui SK, Peterson BA (2008) Necrotizing leukoencephalopathy following CHOP chemotherapy. Leuk Res 32: 1611-1614.
28. Hook CC, Kimmel DW, Kvols LK, Scheithauer BW, Forsyth PA, Rubin J, Moertel CG, Rodriguez M (1992) Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 31: 262-267.
29. Oka M, Terae S, Kobayashi R, Sawamura Y, Kudoh K, Tha KK, Yoshida M, Kaneda M, Suzuki Y, Miyasaka K (2003) MRI in methotrexate-related leukoencephalopathy: disseminated necrotising leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 45: 493-497.
30. Garg RK (2003) Postpartum posterior leukoencephalopathy syndrome. J Assoc Phys India 51: 211-213.
31. Ricard D, Taillia H, Renard JL (2009) Brain damage from anticancer treatments in adults. Curr Opin Oncol 21: 559-565.
32. Pavlakis SG, Frank Y, Chusid R (1999) Hypertensive encephalopathy, reversible occipitoparietal encephalopathy, or reversible posterior leukoencephalopathy: three names for an old syndrome. J Child Neurol 14: 277-281.
33. Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, Yanagi T, Sobue G (1998) Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 19: 415-417.
34. Kwon EJ, Kim SW, Kim KK, Seo HS, Kim do Y (2009) A case of gemcitabine and cisplatin associated posterior reversible encephalopathy syndrome. Cancer Res Treat 41: 53-55.
35. Rajasekhar A, George TJ Jr (2007) Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncologist 12: 1332-1335.
36. Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM (2001) Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol 12: 1327-1329.
37. Ziereisen F, Dan B, Azzi N, Ferster A, Damry N, Christophe C (2006) Reversible acute methotrexate leukoencephalopathy: atypical brain MR imaging features. Pediatr Radiol 36: 205-212.
38. Kelly K, Kalachand R, Murphy P (2008) Bortezomib-induced reversible posterior leucoencephalopathy syndrome. Br J Haematol 141: 566.
39. Martin G, Bellido L, Cruz JJ (2007) Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 25: 3559.
40. Hissink AM, Dunnewijk R, van Ommen B, van Bladeren PJ (1997) Kinetics and metabolism of 1, 4-dichlorobenzene in male Wistar rats: no evidence for quinone metabolites. Chem Biol Interact 103: 17-33.
41. Rathi B, Azad RK, Vasudha N, Hissaria P, Sawlani V, Gupta RK (2002) l-Asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia. Pediatr Neurosurg 37: 203-205.
42. Tsagalou EP, Anastasiou-Nana MI, Margari ZJ, Vassilopoulos D (2007) Possible everolimus-induced, severe, reversible encephalopathy after cardiac transplantation. J Heart Lung Transplant 26: 661-664.
43. Levy CF, Oo KZ, Fireman F, Pierre L, Bania MA, Sadanandan S, Yamashiro DJ, Bender JL (2009) Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer 52: 669-671.
44. Irvin W, MacDonald G, Smith JK, Kim WY (2007) Dexamethasone-induced posterior reversible encephalopathy syndrome. J Clin Oncol 25: 2484-2486.
45. Yoshimoto T, Yagi K, Inoue M, Okamura T, Yasui M, Cyayama K, Nakano T, Tsuchiya H, Kawa K (1997) Leukoencephalopathy probably caused by tacrolimus hydrate after stem cell transplantation in a girl with MDS 7 monosomy. Rinsho Ketsueki 38: 616-621.
46. Kastrup O, Diener HC (2008) TNF-antagonist etanercept induced reversible posterior leukoencephalopathy syndrome. J Neurol 255: 452-453.
47. Kamar N, Kany M, Bories P, Ribes D, Izopet J, Durand D, Rostaing L (2001) Reversible posterior leukoencephalopathy syndrome in hepatitis C virus-positive long-term hemodialysis patients. Am J Kidney Dis 37(E29): 1-6.
48. Re D, Bamborschke S, Feiden W, Schroder R, Lehrke R, Diehl V, Tesch H (1999) Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant 23: 295-298.
49. de Oliveira RA, Fechine LM, Neto FC, Nicodemus JM, Silva GB Jr, Silva LS (2008) Posterior reversible encephalopathy syndrome (PRES) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis. Int Urol Nephrol 40: 1095-1098.
50. Delanty N, Vaughan C, Frucht S, Stubgen P (1997) Erythropoietin-associated hypertensive posterior leukoencephalopathy. Neurology 49: 686-689.
51. Kunschner L, Scott TF (2005) Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 65: 1510.
52. Przepiorka D, Jaeckle KA, Birdwell RR, Fuller GN, Kumar AJ, Huh YO, McCutcheon I (1997) Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant 20: 983-987.
53. Xu N, Zhou W, Li S, Zhou G, Zhang N, Liang J (2009) Clinical and MRI characteristics of levamisole-induced leukoencephalopathy in 16 patients. J Neuroimaging 19: 326-331.
54. Wu VC, Huang JW, Lien HC, Hsieh ST, Liu HM, Yang CC, Lin YH, Hwang JJ, Wu KD (2006) Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients. Medicine (Baltimore) 85: 203-213.
55. Liu JS, Chang YY, Chen WH, Chen SS (1995) Amphotericin B-induced leukoencephalopathy in a patient with cryptococcal meningitis. J Formos Med Assoc 94: 432-434.
56. Walker RW, Rosenblum MK (1992) Amphotericin B-associated leukoencephalopathy. Neurology 42: 2005-2010.
57. Ferry T, Ponceau B, Simon M, Issartel B, Petiot P, Boibieux A, Biron F, Chidiac C, Peyramond D (2005) Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection 33: 151-154.
58. Mahad DJ, Hellden A, Jarvis J, Mitra D, Gholkar A, Chinnery PF (2005) Aciclovir induced posterior leucoencephalopathy. J Neurol Neurosurg Psychiatry 76: 1308-1309.
59. Shuman RM, Leech RW, Alvord ECJ (1975) Neurotoxicity of hexachlorophene in humans. II. A clinicopathological study of 46 premature infants. Arch Neurol 32: 320-325.
60. Nishimune T, Watanabe Y, Okazaki H, Akai H (2000) Thiamin is decomposed due to Anaphe spp. entomophagy in seasonal ataxia patients in Nigeria. J Nutr 130: 1625-1628.
61. Kumar N (2010) Neurologic presentations of nutritional deficiencies. Neurol Clin 28: 107-170.
62. Spampinato MV, Castillo M, Rojas R, Palacios E, Frascheri L, Descartes F (2005) Magnetic resonance imaging findings in substance abuse: alcohol and alcoholism and syndromes associated with alcohol abuse. Top Magn Reson Imaging 16: 223-230.
63. Rubinstein D, Escott E, Kelly JP (1995) Methanol intoxication with putaminal and white matter necrosis: MR and CT findings. AJNR Am J Neuroradiol 16: 1492-1494.
64. Freilich BM, Altun Z, Ramesar C, Medalia A (2007) Neuropsychological sequelae of ethylene glycol intoxication: a case study. Appl Neuropsychol 14: 56-61.
65. Hantson P, Duprez T (2006) The value of morphological neuroimaging after acute exposure to toxic substances. Toxicol Rev 25: 87-98.
66. Salgado RA, Jorens PG, Baar I, Cras P, Hans G, Parizel PM (2009) Methadone-induced toxic leukoencephalopathy: MR imaging and MR proton spectroscopy findings. AJNR Am J Neuroradiol 31: 565-566.
67. Anselmo M, Campos Rainho A, do Carmo Vale M, Estrada J, Valente R, Correia M, Vieira JP, Barata D (2006) Methadone intoxication in a child: toxic encephalopathy? J Child Neurol 21: 618-620.
68. Wolters EC, van Wijngaarden GK, Stam FC (1982) Leukoencephalopathy after inhaling "heroin" pyrosylate. Lancet 2: 1233-1237.
69. Kriegstein AR, Shungu DC, Millar WS, Armitage BA, Brust JC, Chillrud S, Goldman J, Lynch T (1999) Leukoencephalopathy and raised brain lactate from heroin vapor inhalation ("chasing the dragon"). Neurology 53: 1765-1773.
70. Offiah C, Hall E (2008) Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy. Clin Radiol 63: 146-152.
71. Hagel J, Andrews G, Vertinsky T, Heran MK, Keogh C (2005) "Chasing the dragon"-imaging of heroin inhalation leukoencephalopathy. Can Assoc Radiol J 56: 199-203.
72. McKinney AM, Kieffer SA, Paylor RT, SantaCruz KS, Kendi A, Lucato L (2009) Acute toxic leukoencephalopathy: potential for reversibility clinically and on MRI with diffusion-weighted and FLAIR imaging. AJR Am J Roentgenol 193: 192-206.
73. Ryan A, Molloy FM, Farrell MA, Hutchinson M (2005) Fatal toxic leukoencephalopathy: clinical, radiological, and necropsy findings in two patients. J Neurol Neurosurg Psychiatry 76: 1014-1016.
74. Rosenberg NL, Kleinschmidt-DeMasters BK, Davis KA, Dreisbach JN, Hormes JT, Filley CM (1988) Toluene abuse causes diffuse central nervous system white matter changes. Ann Neurol 23: 611-614.
75. Filley CM, Halliday W, Kleinschmidt-DeMasters BK (2004) The effects of toluene on the central nervous system. J Neuropathol Exp Neurol 63: 1-12.
76. Bickel M, Ditting T, Watz H, Roesler A, Weidauer S, Jacobi V, Gueller S, Betz C, Fichtlscherer S, Stein J (2005) Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after "magic mushroom" abuse. Eur J Emerg Med 12: 306-308.
77. Campbell GA, Rosner MH (2008) The agony of ecstasy: MDMA (3, 4-methylenedioxymethamphetamine) and the kidney. Clin J Am Soc Nephrol 3: 1852-1860.
78. Cowan RL, Roberts DM, Joers JM (2008) Neuroimaging in human MDMA (ecstasy) users. Ann N Y Acad Sci 1139: 291-298.
79. Hwang CH (2009) The sequential magnetic resonance images of tri-methyl tin leukoencephalopathy. Neurol Sci 30: 153-158.
80. Huang CC (2004) Carbon disulfide neurotoxicity: Taiwan experience. Acta Neurol Taiwan 13: 3-9.
81. Ku MC, Huang CC, Kuo HC, Yen TC, Chen CJ, Shih TS, Chang HY (2003) Diffuse white matter lesions in carbon disulfide intoxication: microangiopathy or demyelination. Eur Neurol 50: 220-224.
82. Parkinson RB, Hopkins RO, Cleavinger HB, Weaver LK, Victoroff J, Foley JF, Bigler ED (2002) White matter hyperintensities and neuropsychological outcome following carbon monoxide poisoning. Neurology 58: 1525-1532.
83. Miura T, Mitomo M, Kawai R, Harada K (1985) CT of the brain in acute carbon monoxide intoxication: characteristic features and prognosis. AJNR Am J Neuroradiol 6: 739-742.
84. Yoshida T, Andoh K, Fukuhara M (2002) Urinary 2, 5-dichlorophenol as biological index for p-dichlorobenzene exposure in the general population. Arch Environ Contam Toxicol 43: 481-485.
85. Morita M, Ohi G (1975) Para-dichlorobenzene in human tissue and atmosphere in Tokyo metropolitan area. Environ Pollut 8: 269.
86. Hissink AM, Oudshoorn MJ, van Ommen B, van Bladeren PJ (1997) Species and strain differences in the hepatic cytochrome P450-mediated biotransformation of 1, 4-dichlorobenzene. Toxicol Appl Pharmacol 145: 1-9.
87. Bogaards JJ, van Ommen B, Wolf CR, van Bladeren PJ (1995) Human cytochrome P450 enzyme selectivities in the oxidation of chlorinated benzenes. Toxicol Appl Pharmacol 132: 44-52.
88. 14C] benzene in rats after repeated inhalation, oral and subcutaneous doses. Xenobiotica 10: 81-95.
89. Klos C, Dekant W (1994) Comparative metabolism of the renal carcinogen 1, 4-dichlorobenzene in rat: identification and quantitation of novel metabolites. Xenobiotica 24: 965-976.
90. Hill RH Jr, Ashley DL, Head SL, Needham LL, Pirkle JL (1995) p-Dichlorobenzene exposure among 1, 000 adults in the United States. Arch Environ Health 50: 277-280.
91. Yoshida T, Andoh K, Kosaka H, Kumagai S, Matsunaga I, Akasaka S, Nakamura S, Oda H, Fukuhara M (2002) Inhalation toxicokinetics of p-dichlorobenzene and daily absorption and internal accumulation in chronic low-level exposure to humans. Arch Toxicol 76: 306-315.
92. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1999) Dichlorobenzenes. In: IARC monographs on the evaluation of carcinogenic risks to humans. Some chemicals that cause tumours of the kidney or urinary bladder in rodents and some other substances, vol. 73. IARC Press, Lyons, pp 223-276.
93. Eldridge SR, Goldsworthy TL, Popp JA, Butterworth BE (1992) Mitogenic stimulation of hepatocellular proliferation in rodents following 1, 4-dichlorobenzene administration. Carcinogenesis 13: 409-415.
94. Lake BG, Cunninghame ME, Price RJ (1997) Comparison of the hepatic and renal effects of 1, 4-dichlorobenzene in the rat and mouse. Fundam Appl Toxicol 39: 67-75.
95. Aiso S, Arito H, Nishizawa T, Nagano K, Yamamoto S, Matsushima T (2005) Thirteen-week inhalation toxicity of p-dichlorobenzene in mice and rats. J Occup Health 47: 249-260.
96. Umemura T, Kodama Y, Kurokawa Y, Williams GM (2000) Lack of oxidative DNA damage or initiation of carcinogenesis in the kidneys of male F344 rats given subchronic exposure to p-dichlorobenzene (pDCB) at a carcinogenic dose. Arch Toxicol 74: 54-59.
97. Charbonneau M, Strasser J Jr, Lock EA, Turner MJ Jr, Swenberg JA (1989) Involvement of reversible binding to alpha 2u-globulin in 1, 4-dichlorobenzene-induced nephrotoxicity. Toxicol Appl Pharmacol 99: 122-132.
98. Zupko AG, Edwards LD (1949) A toxicological study of p-dichlorobenzene. J Am Pharm Assoc 38: 124-131.
99. Hollingsworth RL, Hoyle HR, Oyen F, Rowe VK, Spencer HC (1956) Toxicity of paradichlorobenzene; determinations on experimental animals and human subjects. AMA Arch Ind Health 14: 138-147.
100. EPA US (2003) Toxicological review and summary documents for dichlorobenzenes (external review draft). EPA/635/R-03/015. US Environmental Protection Agency, Cincinnati.
101. Hallowell M (1959) Acute haemolytic anaemia following the ingestion of paradichlorobenzene. Arch Dis Child 34: 74-77.
102. Campbell DM, Davidson RJ (1970) Toxic haemolytic anaemia in pregnancy due to a pica for paradichlorobenzene. J Obstet Gynaecol Br Commonw 77: 657-659.
103. Harden RA, Baetjer AM (1978) Aplastic anemia following exposure to paradichlorobenzene and naphthalene. J Occup Med 20: 820-822.
104. Wallgren K (1953) Chronische Vergiftungen bel der Herstellung von Mottenmitteln, die grosstenteils aus paradichlorobenzol bestehen. Zentralbl Arbeitsmed Arbeitsschutz 3: 14-15.
105. Petit G, Champeix J (1948) Existe-t-il une intoxication par le paradichlorobenzene? Arch Mal Prof 9: 311-313.
106. Girard R, Toldt F, Martin P, Bourret J (1969) Hemopathies graves et exposition a des derives chlores du benzene (a propas de 7 cas). J Med (Lyon) 50: 771-773.
107. Weller RW, Crellin AJ (1953) Pulmonary granulomatosis following extensive use of paradichlorobenzene. AMA Arch Intern Med 91: 408-413.
108. Cotter LH (1953) Paradichlorobenzene poisoning from insecticides. N Y State J Med 53: 1690-1692.
109. Sumers J, Fuhrman M, Kelman A (1952) Hepatitis with concomitant esophageal varices following exposure to moth ball vapors. N Y State J Med 52: 1048-1049.
110. Nalbandian RM, Pearce JF (1965) Allergic purpura induced by exposure to p-dichlorobenzene. Confirmation by indirect basophil degranulation test. JAMA 194: 828-829.
111. Murray SB, Dwight-Johnson M, Levy MR (2009) Mothball induced encephalopathy presenting as depression: it's all in the history. Gen Hosp Psychiatry. doi: 10. 1016/j. genhosppsych. 2009. 04. 008.
112. Kumar N, Dale LC, Wijdicks EF (2009) Mothball mayhem: relapsing toxic leukoencephalopathy due to p-dichlorobenzene neurotoxicity. Ann Intern Med 150: 362-363.
113. Cheong R, Wilson RK, Cortese IC, Newman-Toker DE (2006) Mothball withdrawal encephalopathy: case report and review of paradichlorobenzene neurotoxicity. Subst Abus 27: 63-67.
114. Avila E, Schraeder P, Belliappa A, Faro S (2006) Pica with paradichlorobenzene mothball ingestion associated with toxic leukoencephalopathy. J Neuroimaging 16: 78-81.
115. Feuillet L, Mallet S, Spadari M (2006) Twin girls with neurocutaneous symptoms caused by mothball intoxication. N Engl J Med 355: 423-424.
116. Weintraub E, Gandhi D, Robinson C (2000) Medical complications due to mothball abuse. South Med J 93: 427-429.
117. Reygagne A, Garnier R, Chataigner D, Echenne B, Efthymiou ML (1992) Encephalopathy due to repeated voluntary inhalation of paradichlorobenzene. J Toxicol Clin Exp 12: 247-250.
118. Miyai I, Hirono N, Fujita M, Kameyama M (1988) Reversible ataxia following chronic exposure to paradichlorobenzene. J Neurol Neurosurg Psychiatry 51: 453-454.
119. Frank S, Cohen HJ (1961) Fixed drug eruption due to paradichlorobenzene. N Y State J Med 61: 4079.
120. Hill RH Jr, To T, Holler JS, Fast DM, Smith SJ, Needham LL, Binder S (1989) Residues of chlorinated phenols and phenoxy acid herbicides in the urine of Arkansas children. Arch Environ Contam Toxicol 18: 469-474.
121. Angerer J, Heinzow B, Schaller K, Weltle D (1992) Determination of environmental caused chlorophenol levels in urine of the general population. Fresenius' J Anal Chem 342: 433-438.
122. Morita S, Miwa H, Kihira T, Kondo T (2003) Cerebellar ataxia and leukoencephalopathy associated with cobalamin deficiency. J Neurol Sci 216: 183-184.